

**Form 51-102F3**  
**Material Change Report**

**1. Name and Address of Company**

AREV Life Sciences Global Corp. (the "Company")

**2. Date of Material Change**

August 25, 2022

**3. News Release**

A press release was issued on August 25, 2022 and disseminated through Market News and Stockwatch.

**4. Summary of the Material Change**

**SUSTAINN, AREV's Ready to Use Therapeutic Foods discussed in leading article in HealthHIV**

**5. Full Description of the Material Change**

VANCOUVER, BC / August 25, 2022 / AREV LIFE SCIENCES GLOBAL CORP. (CSE: AREV) (OTC: AREVF) ("AREV" or the "Company") AREV Life Sciences Global Corporation announces today the coverage of in [HealthHIV.org](https://healthhiv.org) Article titled *Another Horseman*. The article can be read at <https://healthhiv.org/resource/another-horseman/>.

The article articulates the need to aggressively address the use of Ready to Use Therapeutic Foods to treat Serious & Acute Malnutrition in PEPFAR and Global Fund recipient low & middle income countries (LMIC's).

"The global famine is undermining the efficacy of treatment for infectious diseases in the Global South and eastern Europe, and the data shown by key opinion leaders at AIDS 2022 and in this article demonstrates that clinical nutrition, including RUTF's can be transformative in patient outcomes" stated Mike Withrow CEO of AREV. He went on to say, " We applaud HealthHIV for addressing the global challenge facing the staggering growth of HIV patients facing food insecurity, malnutrition and SAM in the Global South.

SUSTAINN (Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs) is a next generation RUTF being developed by AREV Life Sciences, based in Vancouver. This initiative aims to demonstrate the delivery of measurable therapeutic effect in forthcoming inferiority/superiority studies through a unique next-generation RUTF composition. SUSTAINN is intended to treat inanition, the complex disease state that is currently the culprit in the deaths of nine million people worldwide annually, more than the death toll of AIDS, malaria, and tuberculosis combined. Inanition is clinically characterized by dysbiosis, environmental enteropathy, neurodegenerative disease, organ failure, scurvy, beriberi, Kwashiorkor, and anemia due to SAM.

SUSTAINN is being developed in collaboration with The Richardson Centre for Food Technology and Research, University of Manitoba, TransBiotech, and key opinion leaders in biology, therapeutic development and clinical study design from the Institute of Human Virology, University of Maryland and The Linus Pauling Center at Oregon State University, is in compliance with WHO, and Codex-Alimentarius guidelines in 43 countries. RUTF's are essential therapeutic interventions for the treatment of severe acute malnutrition and currently account for more than US \$440M in 2022 in sales by more than 40 companies. SUSTAINN is being produced

under GMP conditions, which meet relevant export criteria, is aflatoxin free and designed to maintain a shelf life of up to two years under appropriate storage instructions. SUSTAINN provides optimal nutritional support addressing the restoration of gut microbiota, malabsorption associated with cachexia, provides essential nutrition, vitamins, minerals and protein that encourage muscle retention, and metabolic functions including ATP levels and EFA supplementation that encourages neurological development. Further collaborations are in development following meetings at AIDS 2022 with AREV Executive leadership and key opinion leaders in positions of program leadership at PEPFAR, the Global Fund for AIDS TB and Malaria, UNAIDS USAID and the World Food Program.

Innovations in RUTFs have demonstrated significant clinical benefits. Supporting neurological growth and function through the provision of essential fatty acids (“EFA”) in SAM patients was studied in a randomized, triple-blinded, controlled clinical trial by Wiley and published in the *British Journal of Nutrition*. This trial demonstrated that DHA Omega-3 supplements boost cognition in malnourished Malawian children. Low linoleic acid foods with added DHA given to Malawian children with severe acute malnutrition to improve cognition. Additional innovations utilizing probiotics to restore microbiome in SAM patients have demonstrated significant improvements in dysbiosis and enteropathy, two clinical presentations that contribute to malabsorption syndrome, involuntary weight loss and subsequent drug resistance.

The Company is also pleased to announce it has settled \$83,331.12 in debt with Chiron Capital Inc, a Company wholly owned by a Director of the Company, by the issuance of 595,222 Shares at \$0.14.

Participation of the insiders of the Company in the shares for debt constitutes a related party transaction as defined under Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions). Because the Company’s shares trade only on the CSE, the issuance of securities is exempt from the formal valuation requirements of Section 5.4 of MI 61-101 pursuant to Subsection 5.5(b) of MI 61-101 and exempt from the minority approval requirements of Section 5.6 of MI 61-101 under 5.7(b).

For further information, contact Mike Withrow, [mike@AREVBrands.com](mailto:mike@AREVBrands.com) 778-929-6536. For more information visit <https://www.arelifesciences.com/>.

**6. Reliance on subsection 7.1(2) or (3) of National Instrument 51 – 102**

Not applicable.

**7. Omitted Information**

Not applicable.

**8. Executive Officer**

Mike Withrow,  
CEO and Director  
Phone: (778) 379-8551

**9. Date of Report**

August 25, 2022